TrialHaematologica2017

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma.

Anas Younes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.